https://takeda.com

Takeda Pharmaceuticals: Global HomepageTakeda is a patient-focused, R&D-driven global biopharmaceutical company committed to bringing Better Health and a Brighter Future.Takeda Pharmaceuticals: Global Homepage AboutOur CompanyLeadershipCorporate ResponsibilityChevron rightCorporate SustainabilityChevron rightSustainability ApproachAccess to MedicinesSustainability DisclosuresEthics & DisclosuresChevron rightEthicsTransparency DisclosuresPositionsCorporate GivingCorporate GovernanceChevron rightGovernance StrategyGovernance StructureCharters and ReportsScienceAreas of FocusResearch and DevelopmentPipelineProductsChevron rightOur ProductsManufacturingSuppliersClinical TrialsOur ImpactOur StoriesNewsroomPress ReleasesStatementsMedia ResourcesInvestorsOverview Financial ResultsInvestor EventsInvestor ContactCareersAboutOur CompanyLeadershipCorporate ResponsibilityCorporate SustainabilitySustainability ApproachAccess to MedicinesSustainability DisclosuresEthics & DisclosuresEthicsTransparency DisclosuresPositionsCorporate GivingCorporate GovernanceGovernance StrategyGovernance StructureCharters and ReportsScienceAreas of FocusResearch and DevelopmentPipelineProductsOur ProductsManufacturingSuppliersClinical TrialsOur ImpactOur StoriesNewsroomPress ReleasesStatementsMedia ResourcesInvestorsOverview Financial ResultsInvestor EventsInvestor ContactCareersSearch...Open Location FinderGLOBALVerticalLineENSearchTakeda Pharmaceuticals: Global HomepageFrom the heart: Meet our 2024 global CSR partnersLearn MoreRecent NewsTakeda to Present Additional Clinical Trial Study Data Highlighting the Impact of Orexin Agonist TAK-861 on the Burden of Narcolepsy at Sleep Europe 2024CalendarSeptember 19, 2024Takeda Commits Over $32 Million in Five New Global Corporate Social Responsibility Partnerships To Further Drive Health Impact in 93 CountriesCalendarSeptember 18, 2024Takeda Receives European Commission Approval for ADZYNMA®▼ (Recombinant ADAMTS13) as the First and Only Recombinant ADAMTS13 Replacement Therapy for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)CalendarAugust 7, 2024Takeda Announces First Quarter FY2024 Results – Strong Performance by Growth & Launch Products; Advancements in Promising Late-Stage PipelineCalendarJuly 31, 2024View AllWe exist to create better health for people and a brighter future for the world. While the science and technology we advance are constantly evolving, our ambition remains. We move science forward, so we can transform more lives.Better Health, Brighter FutureJoin UsWork with globally diverse colleagues who are committed to bringing Better Health to people and a Brighter Future to the world.FIND OUT MOREInvestorsDiscover our balanced, diverse portfolio and strategy for sustainable, patient-centered and resilient growth.FIND OUT MORER&DFueled by our inherent curiosity, we translate science into highly innovative, life-transforming medicines.FIND OUT MOREOur Areas of FocusGastrointestinal and InflammationUnderstanding and addressing life-limiting gastrointestinal and inflammatory diseasesGo to Gastrointestinal and Inflammation pageRare DiseasesWorking to transform treatments in immunology, hematology, metabolic and lysosomal storage disordersGo to Rare Diseases pagePlasma-Derived TherapiesImproving the lives of patients with rare and complex chronic diseases through innovation in plasmaGo to Plasma-Derived Therapies pageOncologyAspiring to cure cancer, with inspiration from patients and innovation from everywhereGo to Oncology pageNeuroscienceDriving medical innovation for patients with neurological diseasesGo to Neuroscience pageVaccinesAddressing unmet global health needs through vaccine development against infectious diseasesGo to Vaccines pageSign up for investors newsletterStay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planetSign upLinkedInYouTubeLocationsContact usCareersFinancial HighlightsHCPsPatientsThis website provides information about Takeda's worldwide business. For specific information about our local markets, please use the country selector.Terms and ConditionsPrivacy NoticeCookie PolicyAccessibility StatementCopyright 1995-2024 Takeda Pharmaceutical Company Limited. All rights reserved.Back to topenen1727135428https://takeda.com

تعديل موقعك؟

ماذا تفعل؟